For Personalis's NeXT Personal liquid biopsy test, how can we optimize sensitivity for detecting minimal residual disease while maintaining affordability for patients?

Introduction

Optimizing sensitivity for detecting minimal residual disease (MRD) in Personalis's NeXT Personal liquid biopsy test while maintaining affordability presents a critical trade-off. This scenario involves balancing advanced technology with cost considerations to ensure both clinical efficacy and patient accessibility. I'll address this challenge by analyzing key factors, proposing strategies, and recommending a path forward.

Step 1

Clarifying Questions (3 minutes)

• Context: I'm thinking about the current market positioning of NeXT Personal. Could you provide more details on our target patient population and how we currently price the test compared to competitors?

Why it matters: Helps understand our market strategy and pricing flexibility Expected answer: Targeting cancer patients post-treatment, priced in the mid-range Impact: Informs potential for price adjustments or market repositioning

• Business Context: Based on our revenue model, I assume reimbursement from insurance companies plays a significant role. How does our current reimbursement rate compare to our costs, and what's the outlook for future coverage?

Why it matters: Affects our ability to absorb costs or pass them to payers Expected answer: Reimbursement covers costs with slim margins, future coverage expanding Impact: May limit room for increasing costs without affecting affordability

• User Impact: Considering the critical nature of MRD detection, I'm curious about the current sensitivity levels and how they compare to patient and oncologist expectations. What feedback have we received?

Why it matters: Helps prioritize sensitivity improvements against current satisfaction Expected answer: Good satisfaction, but room for improvement in early detection Impact: Could justify investing in sensitivity if it significantly improves outcomes

• Technical: Given the rapid advancements in sequencing technology, what are our current technical limitations in improving sensitivity, and what breakthroughs are on the horizon?

Why it matters: Identifies potential avenues for improvement and their feasibility Expected answer: Current limitations in sample preparation, potential for improved algorithms Impact: Guides focus on near-term achievable improvements vs. long-term research

• Resource: Thinking about our R&D capacity, what's our current allocation between improving sensitivity and reducing costs? How flexible is this?

Why it matters: Determines our ability to shift resources to address this trade-off Expected answer: 60% sensitivity, 40% cost reduction, some flexibility to adjust Impact: Informs potential strategies for reallocating resources